BIIB250110C146000
- 0.00
- 0.000.00%
Biogen Newsroom
Peering Into Biogen's Recent Short Interest
Biogen Appoints Feire as Head of Business Development and External Innovation
Biogen Appoints Adam Feire as Head of Business Development and External Innovation
Has Jim Cramer Lost Faith in Biogen Inc. (BIIB)'s Struggles With Alzheimer's and MS Challenges?
S&P 500 Positive for 'First Five Days,' Huang Sees Decades till Quantum | Wall Street Today
Wednesday Market Falls, Quantum Computing Pulls Back Hard on Treasury Yield Crunch | Live Stock
Biogen Price Target Cut to $220.00/Share From $302.00 by Truist Securities
Biogen Is Maintained at Buy by Truist Securities
Biogen Analyst Ratings
Truist Financial Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $220
Solid Biosciences Stock Jumps 11% Post-market on FDA Update
Tuesday Market Pulls Back After Nvidia All Time High | Wall Street Today
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
HealthTech Business Organisation Study: How to Organize Digital Health Businesses, Especially at Large Pharma and MedTech Companies - ResearchAndMarkets.com
Market Sells CES Tech News, ISM Tuesday as Nvidia Champions Robots Monday | Live Stock
RBC Capital Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $231
RBC Cuts Price Target on Biogen to $231 From $260, Keeps Outperform Rating
Biogen to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Market Climbed Monday Just Past Santa Rally High Water Mark | Wall Street Today
CES Tech Conference Week Starts with Nvidia and Chips Climbing | Live Stock